Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT04627012
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Lenvatinib — DRUG
    12 mg (or 8 mg) once daily (QD) oral dosing.
  • Opdivo — DRUG
    3mg/mg intravenously every 3 weeks
  • Camrelizumab — DRUG
    200mg intravenously every 3 weeks
  • Keytruda — DRUG
    200mg intravenously every 3 weeks
  • Toripalimab — DRUG
    240mg intravenously every 3 weeks
  • Sintilimab — DRUG
    200mg intravenously every 3 weeks
  • Tislelizumab — DRUG
    200mg intravenously every 3 weeks

Study Details

For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC. This study will create a database that will provide clinical parameters and outcomes of patients undergoing Lenvatinib and anti-PD1 antibody as part of their standard of care in hopes of answering key clinical questions.

Key Dates

Start date
Jan 1, 2018
Status verified
Mar 2024
Primary completion
Dec 30, 2021
Completion
Jul 1, 2023

Study Design

Enrollment
600 participants (actual)

Primary Outcome Measure

Progression-Free-Survival(PFS) [ Time Frame: 24 months ]

Related Studies